Tuesday 16 December 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Andres Rackear becomes senior VP of legal affairs at NPS

Andres Rackear becomes senior VP of legal affairs at NPS

3 December 2007

New Jersey, USA-based biopharmaceutical firm NPS Pharmaceuticals has promoted Andres Rackear to the position of senior vice president of legal affairs and general counsel. In addition, it has appointed Luke Beshar senior vice president and chief financial officer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

Rosemont Pharma appoints new CEO as business expands globally
Pharmaceutical
Rosemont Pharma appoints new CEO as business expands globally
16 December 2025
Pharmaceutical
Enhertu approved in USA for 1st-line HER2+ metastatic BC
16 December 2025
Pharmaceutical
Lunit links up with Daiichi Sankyo in oncology
16 December 2025
Pharmaceutical
Deals empower Bicycle’s potential in radiopharma
16 December 2025
Pharmaceutical
FDA eliminates major barrier to using real-world evidence in reviews
16 December 2025
Biotechnology
MHRA approves GSK’s Exdensur
16 December 2025
Biotechnology
Saphnelo approved in the EU for sc self-administration
16 December 2025

Company Spotlight

Arcus Biosciences
A clinical-stage biopharmaceutical company headquartered in Hayward, California (San Francisco Bay Area). The company conducts discovery and clinical development primarily in the U.S., with global trial operations supported through external partners and clinical sites.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze